| First Author | Guerrini MM | Year | 2015 |
| Journal | Immunity | Volume | 43 |
| Issue | 6 | Pages | 1174-85 |
| PubMed ID | 26680207 | Mgi Jnum | J:234672 |
| Mgi Id | MGI:5790554 | Doi | 10.1016/j.immuni.2015.10.017 |
| Citation | Guerrini MM, et al. (2015) Inhibition of the TNF Family Cytokine RANKL Prevents Autoimmune Inflammation in the Central Nervous System. Immunity 43(6):1174-85 |
| abstractText | The central nervous system (CNS) is an immunologically privileged site protected from uncontrolled access of T cells by the blood-brain barrier (BBB), which is breached upon autoimmune inflammation. Here we have shown that receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL) on T cells regulates C-C type chemokine ligand 20 (CCL20) production by astrocytes and T cell localization in the CNS. Importantly, mice specifically lacking RANKL in T cells were resistant to experimental autoimmune encephalomyelitis (EAE) due to altered T cell trafficking. Pharmacological inhibition of RANKL prevented the development of EAE without affecting the peripheral immune response, indicating that RANKL is a potential therapeutic target for treating autoimmune diseases in the CNS. |
